Trial Profile
Phase II trial of HM781-36B in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of or unfit for platinum-containing therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Mar 2019 Planned End Date changed from 1 Aug 2016 to 1 Jul 2019.
- 14 Mar 2019 Planned primary completion date changed from 1 Aug 2016 to 1 Jul 2019.
- 07 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.